New drug aims to rival standard treatment for blinding eye disease
NCT ID NCT07389577
First seen Feb 05, 2026 · Last updated May 20, 2026 · Updated 13 times
Summary
This study tested a new medicine called JL14002 against an existing drug (ranibizumab) for wet age-related macular degeneration, a condition that can cause rapid vision loss. The trial involved 443 adults aged 50 to 80 with active disease. The main goal was to see if JL14002 could improve vision as well as the standard treatment over 12 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WET AGE RELATED MACULAR DEGENERATION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Peking Union Medical College Hospital
Beijing, China
Conditions
Explore the condition pages connected to this study.